no doubt the CR rates of >80% from cilta-cel are impressive, but CAR-T therapies remain prohibitively expensive so it’s less clear whether these will ultimately become the SoC for multiple myeloma. Quick google of cilta-cel has a single dose costing upwards of $300,000 USD. So it would appear to me that a combo of carfilzomib and Zantrene would have a place in treatment algorithms given it would be substantially cheaper. Would need quite a bit of economic analysis and more data from cilta-cel trials before we could make a guess either way.
Ann: Expanded Heart Protection Discovery for Zantrene, page-258
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.79 |
Change
-0.075(4.02%) |
Mkt cap ! $304.8M | |||
| Open | High | Low | Value | Volume |
| $1.86 | $1.86 | $1.76 | $348.2K | 192.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5612 | $1.77 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.79 | 3567 | 1 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.78 |
Change
-0.075 ( 5.38 %) |
||||
| Open | High | Low | Volume | ||
| $1.81 | $1.86 | $1.76 | 27553 | ||
| Last updated 15.55pm 14/06/2024 ? | |||||
| RAC (ASX) Chart |